ライフサイエンスコーパス: fractional shortening

1 ardiomyocytes (cell shortening) and in vivo (fractional shortening).

2 enhancement of cytosolic calcium levels and fractional shortening.

3 utput, stroke volume, ejection fraction, and fractional shortening.

4 including hypertrophy, fibrosis, and reduced fractional shortening.

5 ction fraction, with a trend toward lower LV fractional shortening.

6 significant decrease in the left ventricular fractional shortening.

7 s and end diastolic pressures, and increased fractional shortening.

8 eceded left ventricular dilation and reduced fractional shortening.

9 ildren had similar low left ventricular (LV) fractional shortening.

10 ft ventricle, with a significant decrease in fractional shortening.

11 LV end diastolic dimension, and no change in fractional shortening.

12 icular (LV) dimension, wall thicknesses, and fractional shortening.

13 size, and modestly impaired left ventricular fractional shortening.

14 hild over the age of 10 months had depressed fractional shortening.

15 ricular end-diastolic diameter and decreased fractional shortening.

16 ith a significant change in left ventricular fractional shortening.

17 h as peak filling rates and left ventricular fractional shortening.

18 ernal diameter at end-diastole and decreased fractional shortening.

19 on of left ventricular ejection fraction and fractional shortening.

20 ft ventricular wall thickness, and decreased fractional shortening.

21 by maintenance of the ejection fraction and fractional shortening.

22 denced by decreases in ejection fraction and fractional shortening.

23 ular end diastolic diameter and reduction of fractional shortening.

24 received doxorubicin alone (left ventricular fractional shortening: -0.82, 95% CI -1.31 to -0.33; end

25 nd vehicle (39.2 + or - 2.07%), increased LV fractional shortening 1.25-fold over wild-type MSCs and

26 ion fraction 28.8%+/-9.6% vs. 44.4%+/-11.5%; fractional shortening 12.7%+/-5.1% vs. 23.6%+/-6.2%); ho

27 mals that received placebo had a decrease in fractional shortening (-12+/-12%) (P<0.05).

28 In contrast, myocyte fractional shortening (14.1+/-.9% versus 11.1+/-.9%, P<0

29 pertrophy and displayed a strong decrease in fractional shortening (14.6+/-1.6% versus 27.6+/-1.4% in

30 train (20% versus 23%; P=<0.001) and midwall fractional shortening (15.9% versus 16.7%; P=0.001) were

31 - 0.17 mm vs. 4.19 +/- 0.09 mm, P < 0.005; % fractional shortening, 15 +/- 2 vs. 36 +/- 2, P < 0.005)

32 scores (+4.2 vs. +4.2), and left ventricular fractional shortening (16% vs. 17%) at diagnosis were si

33 g, when there was significant deterioration (fractional shortening 18.3 +/- 2.4% vs. 46.9 +/- 2.6%, p

34 Patients with both fulminant (fractional shortening 19 +/- 4%) and acute myocarditis (

35 5.7+/-0.3 mm, P:<0.001) and showed global (% fractional shortening 19.1+/-2.5 versus 55.3+/-2.2, P:<0

36 2.06; P=0.036), worse left ventricular (LV) fractional shortening (19.7+/-1.5% versus 27.2+/-1.5%, P

37 and derived measurements such as the percent fractional shortening (2=.5, P<.01), and left ventricula

38 stitution, improved echocardiography-derived fractional shortening (20.25% and 19.26%, respectively,

39 as significantly better than in MI-controls (fractional shortening 21% versus 16%, P=0.01; fractional

40 e until 16 weeks (ejection fraction, -45.6%; fractional shortening, -22.6%).

41 t-ventricular ejection fraction=45 +/- 2.6%; fractional shortening=22.9 +/- 1.6%; TH = 43% [25%, 45%]

42 ejection fraction (56.2+/-3.5; P=0.029) and fractional shortening (24.3+/-2.1; P=0.03) were improved

43 +/-1.3%, P<0.05) dimensions and augmented LV fractional shortening (24.7+/-10.5%, P<0.03).

44 recovery of 56%; ejection fraction=50+/-1%; fractional shortening=26+/-0.6% at 5 mins, n=3), but was

45 ventricular ejection fraction=51.7 +/- 1.1%; fractional shortening=26.7 +/- 0.7%) than in animals fro

46 tening (ejection fraction %, 54.76 +/- 0.67; fractional shortening %, 27.53 +/- 0.50) compared with s

47 that received MMP inhibitor had no change in fractional shortening (-3+/-13%), whereas animals that r

48 actile function measured as left ventricular fractional shortening (30 +/- 3% Galpha(q) versus 43 +/-

49 nant myocarditis had dramatic improvement in fractional shortening (30 +/- 8%) compared with no impro

50 WT versus 3.1+/-0.1 mm r/r, P<0.013); better fractional shortening (30+/-2% WT versus 46+/-4% r/r; P<

51 within 5 mins (ejection fraction=64+/-4% and fractional shortening=36+/-3%, n=6) and heart rate incre

52 infarct area (13.5% +/- 4.1%) and decreased fractional shortening (38% +/- 5%).

53 A mice (ejection fraction %, 71.60 +/- 4.02; fractional shortening %, 39.63 +/- 3.23).

54 Left ventricle fractional shortening (39.1+/-6.2 versus 47.1+/-6.9%) an

55 (MHC) isoform switch and fibrosis, decreased fractional shortening (39.8 +/- 1.4 FA versus 27.9 +/- 1

56 n-induced cardiac hypertrophy with preserved fractional shortening (39.9+/-1.2% versus 25.9+/-2.6% in

57 nesis and maintained functional performance (fractional shortening, 39% versus 25.2% in Puma(-/-) ver

58 ion and depressed systolic function (percent fractional shortening, 39+/-4 versus 23+/-4; P=0.042).

59 tening (ejection fraction %, 73.06 +/- 6.31; fractional shortening %, 42.33 +/- 5.70) compared with s

60 dimensions, and ameliorated the decrease in fractional shortening (42+/-2% versus 34+/-4%).

61 5% in GqTG; P=0.001), which improved percent fractional shortening (43+/-3% versus 27+/-3%; P=0.017),

62 ce showed an improvement in left ventricular fractional shortening (44.3 +/- 13.3% treated versus 37.

63 ntrols (ejection fraction %, 73.57 +/- 0.20; fractional shortening %, 46.75 +/- 0.38).

64 ion (59 %) of isolated papillary muscle, (2) fractional shortening (50 %), amplitude of the Ca(2+) tr

65 with increases in stroke volume (15 [2] mL), fractional shortening (8% [1]), and ejection fraction (7

66 The z scores for LV fractional shortening (a measure of cardiac function) we

67 progressive decline in left ventricular (LV) fractional shortening accompanied by ventricular dilatio

68 ocyte contractility showed a 74% increase in fractional shortening, accompanied by 115% increase in v

69 Both grafts led to better fractional shortening (AdCMVhBcl-2/mH9c2: 0.21+/-0.03; m

70 left ventricular mass, and left ventricular fractional shortening (adjusted HR, 1.23; 95% CI, 1.09-1

71 or congestive heart failure and decreased LV fractional shortening among those with familial DCM (n=7

72 lsequestrin developed CHF (50.9% decrease in fractional shortening and 56.4% increase in lung weight,

73 ine perfusate calcium of 1.2 mmol/L, myocyte fractional shortening and [Ca2+]i transients were simila

74 LV) mass, wall thickness, contractility, and fractional shortening and above normal LV afterload.

75 sed, with mutant hearts exhibiting decreased fractional shortening and an immature conduction pattern

76 dministration also resulted in a decrease in fractional shortening and an increase in Tei index, sugg

77 ll mouse hearts exhibited a 36% reduction in fractional shortening and an increased diastolic ventric

78 These abnormalities translate into reduced fractional shortening and cardiac contractility at the i

79 Fractional shortening and cardiac output were also signi

80 andard echocardiographic readouts, including fractional shortening and cardiac output, remained uncha

81 tal wall thickness z-scores and increased LV fractional shortening and contractility up to age 2 year

82 9 versus 1.92+/-0.13 microm/s), whereas both fractional shortening and contraction rates are not diff

83 phy revealed significantly increased percent fractional shortening and decreased left ventricular end

84 cardiomyopathy with up to a 65% decrease in fractional shortening and die prematurely.

85 Fractional shortening and dimension at the end of therap

86 entricular mass reduction, and depression of fractional shortening and ejection fraction in tafazzin-

87 howed left ventricular hypertrophy and lower fractional shortening and ejection fraction in VD-defici

88 With candesartan pretreatment, LV fractional shortening and ejection fraction increased (P

89 At 4 weeks, fractional shortening and ejection fraction were determi

90 depressed ventricular function with reduced fractional shortening and ejection fraction, and myocard

91 ic volume and smaller decreases in long-axis fractional shortening and ejection fraction.

92 bnormal cardiac contractility as measured by fractional shortening and ejection fraction.

93 orubicin chemotherapy, mean left ventricular fractional shortening and end-systolic dimension Z score

94 I tissue resulted in significant increase in fractional shortening and improved systolic function.

95 rdiac dysfunction characterized by decreased fractional shortening and interstitial and perivascular

96 both strains had dilated LVs with decreased fractional shortening and lower ejection fractions.

97 ancing age, LV dimensions decreased, whereas fractional shortening and LV wall thickness increased co

98 The KD mice had normal fractional shortening and no heart failure, cardiac hype

99 time delayed and progressive improvement in fractional shortening and other measures of ventricular

100 ence of high-perfusate calcium, both myocyte fractional shortening and peak systolic [Ca2+]i were dep

101 In the control and C+GH groups, myocyte fractional shortening and peak systolic [Ca2+]i were sim

102 failure, mdx-S2808A mice exhibited improved fractional shortening and reduced cardiac dilation.

103 ratios and regional function as measured by fractional shortening and regional work.

104 rtrophy, but it significantly improved basal fractional shortening and responsiveness to beta-adrener

105 , GBS subjects also had increased LV midwall fractional shortening and RV fractional area change.

106 ween serial change in both LV mass index and fractional shortening and subsequent cardiac failure per

107 e ACi group 4 weeks after pressure overload, fractional shortening and the rate of left ventricular p

108 e of zSTARS knockdown, resulting in improved fractional shortening and ventricular end-diastolic dime

109 vement in load-dependent (ejection fraction, fractional shortening) and load-independent (preload rec

110 trophy and enhanced contractility (increased fractional shortening) and no signs of heart failure.

111 t failure (as documented by >25% decrease in fractional shortening) and were randomized to receive ei

112 % increase in LV dimension, a 56% fall in LV fractional shortening, and a 33% decline in myocyte velo

113 left ventricular end diastolic diameter and fractional shortening, and a dramatic increase of life s

114 end-systolic stress, a decrease in long-axis fractional shortening, and a fall in ejection fraction f

115 ventricular end-diastolic diameter, reduced fractional shortening, and decreased relative wall thick

116 tional parameters such as ejection fraction, fractional shortening, and E/A ratio in the Ad.Trx1-admi

117 ad decreased end-diastolic volume, long-axis fractional shortening, and ejection fraction (0.60+/-0.1

118 both strains of mice had a similar LV size, fractional shortening, and ejection fraction by echocard

119 ed left ventricular end-systolic dimensions, fractional shortening, and ejection fraction in mice wit

120 left-ventricular (LV) hypertrophy, decreased fractional shortening, and increased LV end-diastolic pr

121 rd normal values in LV dimension, afterload, fractional shortening, and mass, but all these parameter

122 Vegetation size, left ventricular fractional shortening, and onset of aortic valvular regu

123 lic blood pressure, LV ejection fraction, LV fractional shortening, and systolic wall thickness were

124 se of left ventricular ejection fraction and fractional shortening, and the decreased levels were sim

125 ACV mice displayed increased heart rates and fractional shortening as assessed by echocardiography.

126 3 (P<0.05), including ejection fraction and fractional shortening as compared with groups 1 and 2.

127 ficantly attenuated DOXO-induced decrease in fractional shortening as measured by blinded echocardiog

128 nt increase in +dL/dt and -dL/dt and greater fractional shortening as measured by edge detection (P<0

129 gnificant hypertrophy, dilation, and reduced fractional shortening, as revealed by gated cardiac MRI

130 mong infants without HIV infection, the mean fractional shortening at 10 to 14 months was 38.1 percen

131 Among HIV-infected infants, the mean fractional shortening at 10 to 14 months was similar in

132 he level of betaARKct protein expression and fractional shortening at 12 weeks after TAC.

133 ane protection (p=0.04) for left ventricular fractional shortening at 5 years in girls (1.17, 0.24-2.

134 monstrated greater protection of border zone fractional shortening at 6 weeks.

135 In multivariate modeling, fractional shortening at the endocardium (relative risk

136 ase, confidence interval [CI] 1.27 to 2.39), fractional shortening at the midwall (RR 1.29 per five-u

137 al improvement measured by echocardiography (fractional shortening at week 4: 27.2+/-1.3% versus 22.3

138 LV systolic and diastolic function declined (fractional shortening before the race, 39.6 +/- 0.65%; a

139 milar left ventricular systolic pressure and fractional shortening but more hypertrophy, fibrosis, an

140 In the vehicle group, fractional shortening by echocardiography decreased (-23

141 ricular end systolic diameter, and decreased fractional shortening by echocardiography.

142 gnificant improvements in ejection fraction, fractional shortening, cardiac index, LV dP/dt40, LV neg

143 sumption led to cardiac hypertrophy, reduced fractional shortening, cell shortening, and impaired int

144 evealed LV dilation, as well as decreased LV fractional shortening (CIH, 29.7+/-9.8%; HC, 37.4+/-7.1%

145 F resulted in a decrease in left ventricular fractional shortening compared with controls (P<0.001).

146 ar dysfunction assessed as percent change in fractional shortening compared with controls.

147 ventricular dilatation and deterioration of fractional shortening compared with placebo-treated mice

148 ography showed the shPHD2 group had improved fractional shortening compared with the shScramble group

149 of ventricular myocyte Ca(2)+ transients and fractional shortening (contraction) and the spontaneous

150 Cardiac performance measured as fractional shortening decreased proportionally with decr

151 hich coincided with decreased left ventricle fractional shortening (-Delta11%; P<0.05) at 7 days post

152 nterstitial collagen, and did not improve LV fractional shortening despite decreased LVES pressure.

153 -systolic dimensions, ejection fraction, and fractional shortening) deteriorated in TNC-deficient mic

154 currents, [Ca2+]i transient amplitudes, and fractional shortening did not differ between nonrejectin

155 tress, whereas at 10 months, wall stress and fractional shortening did not improve.

156 local measurements of LV wall thickness and fractional shortening differed from central measurements

157 n challenge, NOS2-deficient mice had greater fractional shortening, dP/dt(max), and Slope(LVESPD) tha

158 ge in left ventricular (LV) mass and percent fractional shortening during Ang II treatment.

159 okine levels, reduced ejection fraction, and fractional shortening (ejection fraction %, 54.76 +/- 0.

160 mice showed preserved ejection fraction and fractional shortening (ejection fraction %, 73.06 +/- 6.

161 hy characterized by significant reduction in fractional shortening, ejection fraction, and a reduced

162 diography showed significant improvements in fractional shortening, ejection fraction, and stroke vol

163 diastolic volume, and mass were greater, but fractional shortening, ejection fraction, and the maximu

164 Baseline fractional shortening, ejection fraction, isovolumic rel

165 icant abnormalities in mean left ventricular fractional shortening, end-diastolic dimension, contract

166 howed significant improvement of ventricular fractional shortening, end-systolic dimension, and end-d

167 increased by 15% from control values, and LV fractional shortening fell by 20%.

168 For example, the mean LV fractional shortening fell by approximately two SD in bo

169 m (P<0.01), with an accompanying increase in fractional shortening from 14+/-7% to 20+/-10% (P=0.05).

170 Doxorubicin decreased left ventricular fractional shortening from 57+/-2% to 47+/-1% (P<0.001)

171 At baseline, SHHF rats had decreased fractional shortening (FS) (31+/-3% versus 67+/-3% in WK

172 myocardial infarction (MI) (left ventricular fractional shortening (FS) = 24 +/- 1%; n = 15) evoked l

173 Mean fractional shortening (FS) and afterload were compared f

174 The steady-state increases in fractional shortening (FS) and peak-systolic [Ca2+]i in

175 Fractional shortening (FS) at echocardiography defined M

176 ociated with increased left ventricular (LV) fractional shortening (FS) during tilt testing, which is

177 o the echocardiogram before left ventricular fractional shortening (FS) improved to 20% and 30% (comp

178 children who, at baseline, had depressed LV fractional shortening (FS) or contractility; increased L

179 itively related to log-QRS duration, whereas fractional shortening (FS) was inversely related (p < 0.

180 Moreover, tadalafil preserved fractional shortening (FS: 31+/-1.5%) compared to contro

181 ions, corrected ejection time (ETc), percent fractional shortening (%FS), VCFc, and ESSm were determi

182 entricular systolic function (predoxorubicin fractional shortening [FS] 61+/-2%, postdoxorubicin FS 4

183 ed 2 weeks later to evaluate heart function (fractional shortening [FS]), end-diastolic diameter, and

184 , 3.68+/-0.12 mm, n=7; P<0.05) and increased fractional shortening (Gq, 32+/-1%, n=12; Gq/AC, 41+/-2%

185 ent for posterior wall thickness (ICC=0.65), fractional shortening (ICC=0.64), and septal wall thickn

186 Fractional shortening improved because of a reduction in

187 and decreased cardiac ejection fraction and fractional shortening in aged (24-month-old) mice and An

188 ingle dose of 24 Gy caused a 35% increase in fractional shortening in BN rats compared with a 16% inc

189 c studies demonstrated significantly reduced fractional shortening in chimeric mice (26.6+/-2.3% vers

190 eft ventricular wall thickness and decreased fractional shortening in DKO animals.

191 ar function, including ejection fraction and fractional shortening in group 3 (P<0.02) as compared wi

192 nd end-systolic chamber size, with decreased fractional shortening in tamoxifen-treated 2AxMCM mice.

193 significant improvement of left ventricular fractional shortening in the minicircle vector carrying

194 diography showed significant preservation of fractional shortening in the MN group compared to contro

195 reserve by measuring the increase in myocyte fractional shortening in the presence of high-perfusate

196 so induced functional recovery in myocardial fractional shortening in vivo and preserved contractile

197 3.1(-/-) and WT, except for smaller post-AVB fractional-shortening increase in Cav3.1(-/-).

198 dimension) increased (+10.9+/-1.0%), whereas fractional shortening increased (+17.5+/-4.4%) in NCX an

199 genic male mice had improved heart function; fractional shortening increased by 74%, and diastolic fu

200 Echocardiography revealed decreased fractional shortening, increased end-systolic diameter,

201 Fractional shortening, left ventricular ejection fractio

202 ram, and systolic dysfunction was defined as fractional shortening less than 25%.

203 ac function as measured by echocardiographic fractional shortening (LRS 22.1 and 15.2 respectively, L

204 ystolic dysfunction in both sets of animals (fractional shortening <0.16 by echocardiogram).

205 population, mildly reduced left ventricular fractional shortening (<30%) was more common (36% vs. 3%

206 rmal at baseline (decreased left ventricular fractional shortening [LV FS] and contractility and incr

207 ricular dimensions and decreases ventricular fractional shortening (measured by high-speed video micr

208 .0111) and a significant increase in midwall fractional shortening (MFS) from 14.3% (2.3) to 16.0% (3

209 er LV mass and wall thicknesses and lower LV fractional shortening, midwall shortening, and stress-co

210 hypertrophy, more chamber dilation, reduced fractional shortening, more fibrosis, and impaired survi

211 the 95% PI was -10% to 8%, indicating that a fractional shortening of 32% measured centrally could be

212 Normal Drosophila have a fractional shortening of 87 +/- 4%, whereas cardiomyopat

213 adrenergic regulation of CaV1.2 current and fractional shortening of cardiomyocytes do not require p

214 nificantly reduced heart rates and decreased fractional shortening of Dicer mutant hearts.

215 heart weight to body weight, greatly reduced fractional shortening of the left ventricle, and lethali

216 Echocardiographic fractional shortening on day 28 was significantly higher

217 ns, there were no significant differences in fractional shortening or contraction or relaxation rates

218 th depressed left ventricular (LV) function (fractional shortening or ejection fraction z-score <-2)

219 estive heart failure, lower left ventricular fractional shortening, or higher left ventricular end-di

220 e corresponding values were -8 versus 0% for fractional shortening (P < 0.0001).

221 rved for ejection fraction (R=0.41), midwall fractional shortening (R=0.51), global circumferential s

222 eart failure (documented by >25% decrease in fractional shortening), rats were randomized to receive

223 +/-0.05 cm) and severely depressed function (fractional shortening reduced from 37% to 26%, P<0.02).

224 The systolic stress versus endocardial fractional shortening relationship was similar in DHF an

225 ls, whereas in children infected with HIV-1, fractional shortening remained significantly lower than

226 pairment in systolic function at a time when fractional shortening remains normal.

227 BP-C(C10mut) displayed significantly reduced fractional shortening, sarcomere shortening, and relaxat

228 e was not significantly related to depressed fractional shortening (shortening of 25 percent or loss)

229 doubling end-systolic elastance and raising fractional shortening similarly in CON-treated and HF he

230 Physiological alterations include decreased fractional shortening, systolic and diastolic dysfunctio

231 xhibited a significantly greater decrease in fractional shortening than athletes who were homozygous

232 and ARVMs from female rats displayed greater fractional shortening than males, and female ARVMs and m

233 mensions that were significantly smaller and fractional shortening that was significantly greater in

234 Heart rate, ejection fraction, fractional shortening, the threshold for opening of mito

235 173.1 +/- 40.1% of B, P = 0.01; and systolic fractional shortening to 180 +/- 29.7% of B, P = 0.01 oc

236 s, LV systolic and diastolic dimensions, and fractional shortening to age, sex, body mass index, bloo

237 re was an inverse relationship of midwall LV fractional shortening to microtubule protein.

238 z scores for fractional shortening transiently improved before fallin

239 fibrosis, ventricular dilation, and reduced fractional shortening, ultimately resulting in overt HF.

240 7+/-0.1 mm; IDN-1965, 4.2+/-0.1 mm; P<0.01), fractional shortening (vehicle, 30.7+/-1.2%; IDN-1965, 3

241 LPS significantly decreased left ventricular fractional shortening, velocity of circumferential short

242 in wild-type mice decreased left ventricular fractional shortening, velocity of circumferential short

243 Midwall LV fractional shortening versus mean LV wall stress in the

244 i) transients (fluo-3, confocal microscopy), fractional shortening (video motion), and L-type Ca2+ cu

245 The mean left ventricular fractional shortening, wall thickness, and thickness-to-

246 constriction model [at 10 wk postprocedure, fractional shortening was 0.31 +/- 0.02 in the mutant (n

247 Mean fractional shortening was 1% smaller in central measurem

248 Preoperatively, fractional shortening was 18.8+/-5.5% in the stentless g

249 sthoracic echocardiography, left ventricular fractional shortening was 47+/-2%, 44+/-1%, and 24+/-2%

250 cted region, at four weeks after infarction, fractional shortening was 75+/-18% and -3+/-15% of basel

251 -1.5 versus 26.7+/-1.8 mm Hg and LV regional fractional shortening was 9.4+/-1.6% versus 3.0+/-0.6% (

252 IDs, LVIDd, increased ejection fraction and, fractional shortening was also observed in the Grx-1(Tg/

253 For neuromuscular disease (n=139), lower LV fractional shortening was associated equally with both e

254 However, LV cardiomyocyte fractional shortening was decreased in MR versus normal

255 Compared with WT mice, fractional shortening was greater in NOS3-/- and less in

256 weeks after beginning doxorubicin treatment, fractional shortening was greater in NOS3-/- than in WT

257 In the GHS group, LV fractional shortening was higher (29+/-2%) and LV peak w

258 In the pacing CHF and GH groups, LV fractional shortening was higher and LV wall stress lowe

259 In the absence of propranolol, the LV fractional shortening was higher in TG compared with NTG

260 In ART+ infants, LV fractional shortening was higher than in ART- infants; g

261 Fractional shortening was improved by rapamycin treatmen

262 Basal and isoproterenol-stimulated fractional shortening was preserved in female transgenic

263 Fractional shortening was preserved in rats treated with

264 Left ventricular fractional shortening was quantified by echocardiography

265 With pacing CHF, LV fractional shortening was reduced (19+/-1 versus 45+/-1%

266 at 6 and 12 weeks of doxorubicin treatment, fractional shortening was reduced (20.7%+/-2.5% versus 3

267 In the untreated pacing CHF group, LV fractional shortening was reduced (21+/-2% versus 47+/-2

268 In the untreated pacing CHF group, LV fractional shortening was reduced and peak wall stress i

269 Reduced fractional shortening was related to impaired contractil

270 tdrug measurements, reduction in left atrial fractional shortening was significantly less at all time

271 Left ventricular fractional shortening was significantly reduced after do

272 At 8 months, fractional shortening was similar in internal and extern

273 of both groups revealed that left ventricle fractional shortening was similar in NADPH oxidase(-/-)

274 Fractional shortening was similarly enhanced (12.2+/-1.2

275 e in left ventricle function, as measured by fractional shortening, was detected in mice infected wit

276 al function, including ejection fraction and fractional shortening, was quantitated 2 wks and 4 wks a

277 s were lower whereas LV contractility and LV fractional shortening were higher when compared to the H

278 ntricular (LV) mass index, volume index, and fractional shortening were seen in 48, 48, and 46%, resp

279 ts of left-ventricular ejection fraction and fractional shortening were significantly better (P<0.05)

280 ped pressure per gram as well as endocardial fractional shortening were similar in 4-week AS and cont

281 ar function, including ejection fraction and fractional shortening, were improved in group 3 as compa

282 acing therapy in all outcome measures except fractional shortening, which demonstrated a trend toward

283 6 and a QTL near to the marker D19Mit88) for fractional shortening with a LRS of 34.6 and 26.5 respec

284 ss, decreasing LV dimensions, and increasing fractional shortening with advancing age.

285 se was a marker of an attenuated increase in fractional shortening with aging.

286 left ventricular enlargement, mild decreased fractional shortening with increased wall thickness.

287 cyte Ca(2+) transients and enhanced unloaded fractional shortening with no change in SR Ca(2+) pump c

288 failure (hazard ratio 2.20, P=0.005), lower fractional shortening z score (hazard ratio 1.12 per 1 S

289 shortening Z score, higher left ventricular fractional shortening Z score during follow-up, and grea

290 ansplantation, as was lower left ventricular fractional shortening Z score during follow-up.

291 yopathy, and lower baseline left ventricular fractional shortening Z score were associated with incre

292 art failure, and lower left ventricular (LV) fractional shortening z score were independently associa

293 estive heart failure, lower left ventricular fractional shortening Z score, and cause of DCM (P<.001

294 related to higher baseline left ventricular fractional shortening Z score, higher left ventricular f

295 and greater improvement in left ventricular fractional shortening Z score.

296 1), had less-depressed mean left ventricular fractional shortening z scores (-7.85+/-3.98 versus -9.0

297 Mean fractional shortening z scores measured 3.5 to 6.4 years

298 lower nadir CD4 percentage had lower mean LV fractional shortening z scores, whereas the mean z score

299 er cardiac function (LV contractility and LV fractional shortening z scores; all P = .001) and an inc

300 tively associated with left ventricular (LV) fractional shortening (z-score for difference = 1.07; p